Deal to acquire Longboard Pharmaceuticals gives access to Bexicaserin for Dravet Syndrome October 14 2024: H. Lundbeck A/S and Longboard Pharmaceuticals, Inc have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Through the acquisition of Longboard, Lundbeck gains access to…
Category: Epilepsy
Epilepsy drug may treat obstructive sleep apnoea
10 September 2024: Patients taking sulthiame (brand name Ospolot), a drug currently in use for epilepsy, experienced a reduction in their symptoms of obstructive sleep apnoea (OSA) according to results of a clinical trial presented at the European Respiratory Society (ERS) Congress in Vienna Austria [1]. Patients with OSA often snore loudly, their breathing starts…
Managing drug resistant epilepsy (DRE)
Effectiveness of cenobamate and vagus nerve stimulation (VNS) highlighted at recent EAN congress At the recent 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of anti-seizure medication (ASM) cenobamate and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Dravet Syndrome and SCN1A-related epilepsies
New study aims to transform understanding The ‘SCN1A Horizons Natural History Study’ is anticipated to be a milestone in transforming understanding of SCN1A epilepsies, including Dravet Syndrome, one of the most complex and severe developmental and epileptic conditions. The nationwide study aims to define the seizure, neurodevelopmental, and behavioural characteristics of SCN1A-related epilepsies in 400…
Epilepsy associated with CDKL5 Deficiency Disorder
European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder 31 July 2023: Marinus Pharmaceuticals announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to…
Could new materials lead to implantable treatments for epilepsy?
Breakthrough research on materials may help new types of probes be safely implanted in the brain. Bioengineering researchers from the University of Glasgow have investigated new dissolvable coatings which could help safely guide flexible implants into brains to help regulate temporal lobe epilepsy. The development of the material, outlined in an early-view paper in the…
Grant to explore new epilepsy treatment for Tuberous Sclerosis Complex (TSC)
Dr Felix Chan awarded £174k grant to study Tuberous Sclerosis Complex (TSC) and epilepsy by Epilepsy Research UK. The new study will investigate lysine metabolism as a therapeutic target for epilepsy in TSC Research designed with TSC and epilepsy patient community through Tuberous Sclerosis Association and Epilepsy Research UK. A researcher based in Aston Institute for…
‘Microbot’ development could help treat seizures
University of Glasgow researchers are part of a new project which is setting out to develop tiny injectable robots capable of predicting and mitigating epileptic seizures. The project, called CROSSBRAIN, is led by Tor Vergata University of Rome in Italy and is funded by the European Innovation Council. Over the course of the next four…
